Georgia is currently home to 1921 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Atlanta, Augusta, Decatur and Savannah. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma
NCT05257083
Recruiting
The purpose of this study is to compare the efficacy of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in newly diagnosed multiple myeloma patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/26/2025
Locations: Emory University Hospital, Atlanta, Georgia
Conditions: Multiple Myeloma
Register for Updates
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
NCT06972459
Recruiting
The main purpose of this study is to see how orforglipron, compared with placebo, helps reduce body weight in participants with obesity or with overweight and at least one other related health condition (excluding type 2 diabetes). This trial is part of the master protocol study J2A-MC-GZPO. Participation in the study will last about 18 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2025
Locations: Care Access - Decatur, Decatur, Georgia
Conditions: Obesity, Overweight
Register for Updates
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
NCT06528314
Recruiting
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis due to NASH/MASH.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/23/2025
Locations: Akero Clinical Study Site, Atlanta, Georgia
Conditions: NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
Register for Updates
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
NCT06455449
Recruiting
The purpose of this multicenter, randomized, placebo-controlled and double-blind study is to evaluate the efficacy and safety of subcutaneous anifrolumab compared with placebo on the overall disease activity in participants with moderate to severe Idiopathic Inflammatory Myopathies (IIM) \[polymyositis (PM) or dermatomyositis (DM)\] while receiving standard of care (SoC) treatment.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/23/2025
Locations: Research Site, Atlanta, Georgia
Conditions: Polymyositis, Dermatomyositis
Register for Updates
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
NCT06377852
Recruiting
The purpose of this study is to generate evidence on an alternative dosing strategy for CDK4/6 inhibitors to help more patients with Metastatic Breast Cancer (MBC) (age ≥ 65 years) tolerate side effects and stay on treatment longer, to derive the most clinical benefit from these drugs. The primary objective of the CDK Study is to compare time to treatment discontinuation (TTD) on the approved dosing for palbociclib (125 mg orally daily on days 1-21 of 28-day cycle) or ribociclib (600 mg orally... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
05/23/2025
Locations: Emory University Winship Cancer Institute, Atlanta, Georgia
Conditions: Metastatic Breast Cancer
Register for Updates
A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
NCT06297590
Recruiting
The main purpose of this study is to evaluate the safety of LY3954068 in participants with early symptomatic Alzheimer's Disease (AD). The study will also investigate how much LY3954068 gets into the bloodstream and will test the effects of LY3954068 on markers of AD. The study will be comprised of two parts, A and B. Part B is optional, and participants from Part A may also have the opportunity to join an optional bridging period to a separate potential study where participants would receive L... Read More
Gender:
ALL
Ages:
Between 50 years and 85 years
Trial Updated:
05/23/2025
Locations: CenExel iResearch, LLC (CenExel iRA), Decatur, Georgia
Conditions: Alzheimer Disease
Register for Updates
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
NCT06283966
Recruiting
This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
05/23/2025
Locations: Research Site, Atlanta, Georgia
Conditions: COPD (Chronic Obstructive Pulmonary Disease)
Register for Updates
Comparing Telephone Symptom Monitoring Interventions for Managing Symptoms and Psychological Distress During Oral Anti-Cancer Treatment
NCT06279013
Recruiting
In this clinical trial, symptom monitoring (interactive voice response \[IVR\] is compared to automated telephone symptom management \[ATSM\] and telephone interpersonal counseling \[TIPC\]) for reducing symptom burden and psychological distress (depressive and anxiety symptoms) among people receiving oral anti-cancer treatment. Symptoms are the number one driver of treatment interruptions and unscheduled health services use. To reduce the risk of these events, symptom monitoring and management... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2025
Locations: Augusta University Medical Center, Augusta, Georgia
Conditions: Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm
Register for Updates
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
NCT06111235
Recruiting
This is a Phase 3, open-label, randomized trial designed to evaluate the RFS of TURBT followed by cretostimogene grenadenorepvec versus TURBT followed by surveillance for the treatment of participants with IR-NMIBC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2025
Locations: Emory Winship Cancer Center, Atlanta, Georgia
Conditions: Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
Register for Updates
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
NCT06016738
Recruiting
This phase 3 clinical trial compares the safety and efficacy of palazestrant (OP-1250) to the standard-of-care options of fulvestrant or an aromatase inhibitor in women and men with breast cancer whose disease has advanced on one endocrine therapy in combination with a CDK4/6 inhibitor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2025
Locations: Clinical Trial Site, Atlanta, Georgia
Conditions: Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, HER2 Negative Breast Carcinoma
Register for Updates
Study of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living With HIV-1, Two to Less Than 12 Years of Age
NCT05660980
Recruiting
The purpose of the study is to evaluate the pharmacokinetics (PK), safety, tolerability, and acceptability of a long-acting injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to Less Than 12 Years of Age
Gender:
ALL
Ages:
Between 2 years and 11 years
Trial Updated:
05/23/2025
Locations: Site 5030, Emory University School of Medicine NICHD CRS, Atlanta, Georgia
Conditions: HIV-1-infection
Register for Updates
Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare
NCT05658575
Recruiting
The purpose of this trial is to investigate the efficacy and safety of dapansutrile (OLT1177®) tablets in subjects with an acute gout flare.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2025
Locations: Arthritis Center of North Georgia - Gainesville, Gainesville, Georgia
Conditions: Acute Gout Flare, Gout Attack, Gout Flare, Gouty Arthritis, Gout, Arthritis, Joint Pain
Register for Updates